Goldman Sachs: Slightly lowers this year's gambling revenue forecast to an 8% increase year-on-year, continues to be optimistic about Sands China (01928) and Galaxy Entertainment (00027).
The expected performance of Wynn Macau (01128) in the third quarter is expected to exceed expectations, which may bring positive momentum to its stock price in the short term.
Goldman Sachs released a research report stating that the total gambling revenue for the first 12 days of October decreased by 5% year-on-year, lower than expected, compared to a 3% increase in gambling revenue for the first 5 days of the month. Considering factors such as typhoons and travel to overseas countries, the bank believes it is premature to say that the recent positive trend has reversed. The bank believes that the comparison base for November to February next year is still quite favorable.
The bank slightly lowered its forecast for this year's gambling revenue to an 8% year-on-year increase, still bullish on Sands China (01928) and Galaxy Entertainment (00027), both rated "Buy." In addition, it is expected that Wynn Macau (01128) will outperform expectations in the third quarter, potentially bringing positive momentum to its stock price in the short term.
Related Articles

US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.

US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%

US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.

US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%

US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
